|
ConjuChem Biotechnologies develops long-acting peptide-based pharmaceuticals to treat diseases such as congestive heart failure, diabetes, HIV/AIDS, and human growth deficiencies. The company, primarily a research and development operation, fostered a technology that binds peptides to albumin in order to extends the half life of drugs from minutes to days. Its lead candidate, Exendin-4, which could treat type 2 diabetes, is in clinical trials in Europe and North America.
|
| | | Contact Information | |
Address: |
225 President Kennedy Ave., Ste. 3950
Montreal, Quebec H2X 3Y8, Canada
| | Phone: | 514-844-5558 | | Fax: | 514-844-1119 |
|
| Financial
Highlights | | Fiscal Year End: | October | | Revenue (2008): | 1.20 M | | Revenue Growth (1 yr): | (-68.30%) | | Employees (2008): | 40 | | Employee Growth (1 yr): | (-9.10%) |
|
|
Key People
| | • |
Chairman:
Jacques R. Lapointe
| | • |
President and CEO:
Mark D. Perrin
|
|
|
